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The blood-brain barrier (BBB) is a neurobiological frontier that isolates brain tissues from the blood 
vascular system. Its main role is to protect the brain and the central nervous system from external 
fluctuations in hormones, nutrients and drugs, while allowing the passage of water and small 
lipophilic molecules. Diffusion across the BBB can occur through several biological mechanisms, 
but the most common one is simple diffusion, which mainly depends on the size, lipid solubility and 
concentration gradient of the molecule. Because of the highly dense network of capillary 
endothelium cells found in the BBB, most of the drugs are not able to cross this physiological 
barrier. Delivering therapeutic agents to the brain is thus a big challenge, which may prevent 
treatment of important neurological diseases. In order to overcome this difficulty, researchers have 
used nanotechnology to help the passage of drugs across the BBB. Nanotechnology has 
significantly contributed to the field of biotechnology by improving the strategies for drug delivery, 












discuss in more details the anatomical structure and the functions of the BBB, as well as its 
significance in neurological diseases. A closer look will be given at the transport mechanisms 
across the BBB. This review finally explores the most recent advances in the field of 
nanotechnology for drug delivery in the brain, and gives meaningful examples of delivery systems 








The blood-brain barrier (BBB) is a highly 
selective permeability structure designed to 
regulate brain homeostasis and the transport of 
essential molecules to the brain [1,2]. It acts as a 
tight connection between the circulating blood 
and the brain extracellular fluid. Its role is also to 
protect the neurons from bacterial infections and 
from fluctuations in hormones, metabolites and 
nutrients [3,4]. By controlling the environment of 
the nervous tissue of the brain, it is able to 
maintain a proper neuronal transmission. Recent 
advances in molecular neuroscience and 
biochemistry have shaped our understanding of 
the physiology of the BBB and its relationship 
with pathological conditions of the brain. 
However, treatment of diseases of the brain and 
the central nervous system still remains a big 
challenge, mostly because of the fact that 
therapeutic molecules cannot easily cross the 
BBB, and fail to reach specific part of the brain 
[1,5]. Therefore, there is an urgent need to use 
novel approaches for better drug targeting and 
delivering to specific regions of the brain. 
 
The transport of pharmaceutical agents across 
the BBB rely on a variety of mechanisms, one of 
which is the transmembrane passive diffusion, 
which depends on the concentration gradient, as 
well as the size and charge of the molecule [6]. 
However, this process is limited because it 
mostly favors lipid-soluble molecules [7]. Other 
methods such as carrier and receptor-mediated 
transport are also employed to deliver drugs to 
the brain [8], but most of them may do damage 
and cause toxicity to the BBB. The optimal 
method of delivery into the brain should be able 
to accurately target specific areas without 
damaging the BBB. Among the numerous 
approaches available, nanotechnology has 
provided the possibility to deliver therapeutic 
agents into neuronal tissues and cells with high 
safety and specificity [1,3,9]. 
 
This review talks about the characteristics of the 
BBB from a physiological and biological point of 
view, and describes the physical barriers that 
therapeutic agents need to cross in order to 
reach the brain. Moreover, it discusses the 
transport mechanisms across the BBB and 
explains how the use of nanotechnology could 
enhance the delivery of pharmaceutical agents to 
specific areas of the brain. Finally, a closer look 
is given at the impact that nanotechnology has 
on the treatment of brain diseases and disorders. 
 
2. PROPERTIES OF THE BLOOD-BRAIN 
BARRIER 
 
2.1 Function and Physiology of the 
Blood-Brain Barrier 
 
The BBB is constituted of a vast network of 
microcapillaries that isolate brain tissues from the 
substances that circulate into the vascular 
system [10]. The molecular architecture of this 
barrier gives it specific characteristics that enable 
only fat-soluble molecules and compounds with a 
low molecular mass to pass directly through its 
walls [6,11]. Therefore, the BBB protects the 
neuronal tissue from abrupt changes in 
metabolites and exogenous compounds 
circulating in the blood. It also prevents the 
transport of ionic currents and hydrophilic 
compounds to the brain, and protects the 
individual from several pathological conditions 
[3]. Moreover, it plays an important role during 
inflammation of the brain and the central nervous 
system [12]. By becoming more permeable 
during inflammation, it allows phagocytes and 
other immune cells to cross the barrier and to 
fight against bacteria and foreign molecules. 
 
The structural bases of the BBB are the 
endothelial cells, the pericytes and the astrocyte 
end-feet. The astrocytes are important structures 
in the brain that help modulate the permeability 
of the BBB [13]. They can also up regulate many 
features of the BBB, leading to a tighter physical 
barrier and increased expression of transporters 
and specialized enzymes [13]. Tight junctions, 
which mostly consist of transmembrane proteins, 











restrict the passage of bacteria through the BBB, 
while allowing the transport of small hydrophobic 
molecules such as O2 and CO2 [14]. The main 
function of the pericytes is to wrap around 
endothelial cells and to maintain the protection 
and functionality of the brain and nervous system 
[15]. A lack of pericytes in the central nervous 
system can cause BBB to break down [15]. 
Moreover, the elastic properties of the pericytes 
enable them to significantly reduce neuronal 
inflammation by allowing the release of toxic 
substances from the brain. The astrocyte end-
feet, which also encircled the endothelial cells, 
play a major role in maintaining the BBB and in 
facilitating blood flow in the brain [16]. They are 
important in regulating the neuronal metabolism 
and in discharging used or unwanted substrates 
[16]. Other structures such as the extracellular 
base membrane, the microglia and the 
surrounding neurons also form part of the BBB.  
 
2.2 Physical Barriers 
 
The BBB prevents molecules from entering and 
leaving the brain by forming a physical barrier. 
This barrier is larger due to the establishment of 
a network of brain capillaries that isolate the 
brain, and the presence of tight junctions that 
separate the capillary endothelial cells [17]. Tight 
junctions, also known as occluding junctions, 
generate a barrier to the extracellular fluid by 
closely contacting adjacent endothelial cells [18]. 
They practically control which substances can 
pass through the BBB. They are composed of a 
series of transmembrane proteins that are highly 
interconnected. Claudins and occludins are such 
proteins that form the integrity of the tight 
junctions [19,20]. Claudins are small molecules 
that have four transmembrane domains. They 
form the primary seal of the tight junctions 
through the use of disulfide bonds [21]. 
Occludins also span the plasma membrane four 
times but have a different function than the 
claudins. Although they do not directly participate 
in the formation of tight junctions, their main role 
is to maintain the shape and permeability of the 
barrier [1,22]. Junctional adhesion molecules 
(JAM), which are mainly expressed by 
leukocytes and endothelial cells, also play a key 
part in the formation of tight junctions [23,24]. 
They appear to facilitate the interaction between 
leukocytes and endothelial cells, suggesting a 
potential role in mediating the immune activity of 
the BBB during pathological conditions of the 
brain [25]. 
Another important complex of proteins that form 
part of the physical barrier are the adherens 
junctions [26,27]. They perform several tasks 
including the stabilization of cell-cell adhesion, 
and the regulation of intracellular signaling and 
transcriptional regulation [28]. The adherens 
junctions are located just below the tight 
junctions, and can occur in epithelial and 
endothelial tissues [29]. They are composed of 
cadherins, which are part of the transmembrane 
glycoproteins that form homodimers with other 
cadherin molecules and leads to the generation 
of a tightening complex [30,31]. A down-
regulation of the cadherins often results in a loss 
of cell-cell adhesion, which can lead to cell 
proliferation and tumor invasiveness [32]. The 
adherens junctions are also composed of other 
cytoskeleton proteins, such as the catenins, 
which links the actin cytoskeleton with the 
cadherin [33]. 
 
The catenin family is composed of the p120-
catenin, the α-catenin and the β-catenin 
[34,35,36]. By binding to the cadherin, the p120-
catenin helps stabilize the formation of cell-cell 
contacts at the plasma membrane. The p120-
catenin also serves as a regulator of cell motility 
through the actin cytoskeleton [28]. The α-
catenin is a protein that binds to actin filaments 
and plays a major role in maintaining the 
structural integrity of the adherens junctions. 
Moreover, the α-catenin binds to the β-catenin 
[37], which is involved in the regulation of efflux 
transporters of the BBB and in strengthening the 
cell-cell connections mediated by the cadherin. 
Taken all together, the BBB consists of several 
physical connections that create a nearly 
impermeable boundary between the brain and 
the bloodstream, and that help maintain the 
necessary extracellular environment of the 
central nervous system. 
 
3. TRANSPORT MECHANISMS ACROSS 
THE BLOOD-BRAIN BARRIER 
 
Transport across the BBB occurs through 
different mechanisms, the most common ones 
being simple diffusion, carrier-mediated 
transport, facilitated diffusion and receptor-
mediated endocytosis. The characteristics and 
biological properties of each mechanism are 














Table 1. Mechanisms of transport through the blood-brain barrier 
 
Transport mechanism Characteristics Molecules transported 
Simple diffusion Passive and transcellular 
transport 
Small, non-polar and lipophylic 
molecules 
Example: steroid hormones and 
psychoactive drugs 
Carrier-mediated transport Passive transport using 
transport proteins 
Essential amino acids, peptides, 
hormones, glucose and small 
drugs 
Facilitated-diffusion Passive transport through 
transmembrane proteins 
Water, ions, amino acids, 
nutrients and monocarboxyates 
Receptor-mediated 
endocytosis 
Active transport by transcytosis 
across the barrier 
Macromolecules, plasma proteins, 
hormones and peptides. Example: 
insulin, leptin, transferrin and 
Vitamin B6 
 
3.1 Simple Diffusion 
 
Several molecules, including psychoactive drugs, 
move through the BBB by simple diffusion 
[38,39]. This mechanism relies on the size and 
lipid solubility of the substance, but also on the 
concentration gradient across the barrier. This is 
the simplest and most frequent form of transport 
since there is no energy needed. While 
electrostatically charged molecules cannot pass 
through the barrier by simple diffusion, lipophilic 
substances and small molecules like O2 and CO2 
canrapidly penetrate the BBB [38]. Simple 
diffusion can be divided into paracellular and 
transcellular diffusion. Paracellular diffusion 
refers to the transport of substances between 
cells, through the intercellular space. In contrast, 
transcellular diffusion is the passage of 
molecules across cells, through the apical and 
basolateral membranes. Because of the 
presence of tight junctions, passage between the 
cells could not occur in the BBB. 
 
3.2 Carrier-Mediated Transport 
 
In the case of carrier-mediated transport, the 
solute binds to a transport protein located on one 
side of the membrane. A transport protein is an 
integral carrier protein that spans the membrane 
of the endothelial cells. When the solute binds to 
the carrier protein, a conformational change 
occurs in the protein, which result in the transport 
of the solute through its concentration gradient. 
This type of diffusion is passive and does not 
require any form of energy. It mostly contributes 
to the transport of substances such as the 
essential amino acids, small peptides, hormones 
and glucose [40,41]. In the case of glucose, this 
molecule passes through the BBB by binding to 
specific glucose transport proteins that are found 
on the membrane of endothelial cells [42].  
 
3.3 Facilitated Diffusion 
 
Facilitated diffusion is a type of carrier-mediated 
endocytosis, which refers to the passage of 
molecules or ions across a biological membrane 
through specific transmembrane integral proteins 
[43]. During this process, molecules and ions 
move down their concentration gradient in a 
passive way. Channels that open and close to 
regulate the flow of substances across the 
membrane control this type of transport. For 
instance, water molecules can pass through 
aquaporins, which are proteins that form pores in 
the membrane of the endothelial cells [44,45]. 
They selectively allow the passage of water 
molecules through the BBB, while preventing the 
transport of other ions and solutes [45]. 
 
3.4 Receptor-Mediated Endocytosis 
 
Large molecules and aggregates that cannot 
pass through transmembrane proteins can 
penetrate the BBB by receptor-mediated 
endocytosis [46]. During this process, the 
molecule binds to receptors located on the 
surface of endothelial cells and gets incorporated 
by endocytosis. The molecule then gets 
transported across the interior of the cell by 
transcytosis. Alternatively, the substance can get 
incorporated into the endothelial cell by merging 
with the membrane and forming a vesicle that 
migrates inside the cell and releases its content 
upon reaching the other side of the barrier. 
Receptor-mediated transcytosis can mediate the 
transport of plasma proteins such as insulin, and 











energy, mostly from adenosine triphosphate, in 
order to drive the movement of molecules across 
the barrier and against their concentration 
gradient [48]. 
 
4. USE OF NANOTECHNOLOGY-BASED 
DELIVERY PLATFORMS 
 
Because passage of drugs to the central nervous 
system through the BBB is very limited, new 
approaches need to be employed in order to 
improve drug delivery to the brain. Nanocarriers 
are an emerging class of delivery platform that 
can easily transport drugs to the brain and 
several other parts of the body [1,9,49]. They 
exhibit properties that make them very suitable 
for drug delivery across the BBB. Such 
properties include their small size, their 
biocompatibility, their prolonged blood circulation 
time and their nontoxicity [1,50]. Several studies 
have focused on the development of such 
nanotechnology-based systems for the delivery 
of pharmaceutical agents, peptides, recombinant 
proteins, as well as vaccines and nucleotides 
[50,51,52]. The most commonly used delivery 
systems are micelles, liposomes, dendrimers, 
microcapsules and functionalized nanoparticles. 
 
4.1 Polymeric Micelles 
 
Micelles have recently emerged as a promising 
tool for the delivery pharmaceutical drugs 
through the BBB [53,54]. They are spherical 
aggregates of molecules dispersed in a liquid 
colloid [1,55]. They are prepared from a certain 
type of amphiphilic co-polymers that consist of 
both hydrophilic and hydrophobic units of 
monomers, and are a perfect choice to deliver 
drugs with poor liquid solubility. The molecular 
geometry and properties of the molecules that 
form the micelles, such as concentration, pH, 
and ionic strength, dictate the overall size and 
shape of the final structure. An advantage of 
using micelles for drug delivery is that they have 
the ability to significantly increase the 
bioavailability and solubility of pharmaceutical 
drugs [1]. However, because of their sensitivity to 
environmental changes such as dilution and ionic 
strength, micelles are often conjugated to some 
organic compounds that can provide higher 
stability. Several studies used micelles in order to 
deliver hydrophobic drugs across the BBB, one 
of which was able to demonstrate that molecular 
compounds with poor solubility could be loaded 
into very small negatively charged micelles that 
could easily penetrate the BBB [56]. In this study, 
steroidal compounds were delivered to the brain 
through the use of ligand-modified nanomicelles. 
Lactoferrin and sodium alginate–cholesterol 
derivatives were used to develop the 
nanomicelles, and they were shown to 
significantly increase the drug loading capacity 
and prolong the release profile [56]. Polymeric 
micelles can also improve the pharmacological 
activity of drugs by enhancing pharmacokinetics, 
and have been extensively used to deliver 
anticancer agents to the tumor site of the patient 
[57]. They are also used for other medical 
applications, such as cancer chemotherapy [58], 
due to their ability to accumulate and persist 
longer in tumoral tissue [55,58]. Taken all 
together, polymeric micelles can be used as an 
efficient drug delivery platform that could aid in 




Liposomes are spherical vesicles of a lamellar 
phase liquid that are artificially prepared and that 
can be used for administration of pharmaceutical 
compounds [59]. They consist of naturally 
occurring phospholipids and cholesterol, and are 
traditionally prepared by sonication (disruption of 
biological membranes) [60]. Because liposomes 
have a relatively high systemic plasma 
clearance, they get rapidly removed form the 
blood circulation by macrophages [50,59]. With 
the advances in pharmaceutical research, it is 
now possible to increase their half-life by 
incorporating polyethylene glycol (PEG) to 
theirmembrane [61,62]. This coating also 
enables the liposomes to avoid being detected 
by the body's immune system. Another 
advantage in using liposomes is that they can be 
coated with several biological molecules, such as 
ligands, which enable them to target specific 
sites in the brain. A recent study demonstrated 
that coupling the liposomes with PEG and 
targeting molecules could significantly enhance 
drug delivery across the BBB [63]. The scientists 
conducting this research aimed at developing a 
liposome-based vehicle coupled with PEG and 
another small molecule, OX26, which is a very 
efficient targeting antibody in brain drug delivery 
[63]. The therapeutic efficacy of this delivery 
platform was then tested by intravenously 
injection in an animal model of high-grade 
glioma, one of the most frequent types of 
intracranial tumor [63]. They showed that the 
modified liposomes were able to cross the BBB 
and could effectively target the brain glioma cells, 
both in-vitro and in-vivo [63]. Another study has 
coupled the liposomes with PEG and glutathione, 











corticosteroid drug, in an animal model of neuro-
inflammation [64]. Their results showed that 
surface-modified liposomes are effective in 
delivering the drug to the central nervous system, 
and in treating neuro-inflammatory disorders 
such as multiple sclerosis [64]. Such targeting 
delivery system could indeed open up new 
treatment strategies that are non-invasive and 




Dendrimers are branched molecules that have 
received a large attention because of their ability 
to cross the BBB and several other target points 
[65,66]. Their small size and shape allow them to 
penetrate brain endothelial cells and deliver 
drugs to targeted sites of the central nervous 
system [67]. Moreover, their encapsulation 
ability, their low toxicity, as well as their water 
solubility make them appropriate candidates for 
evaluation as drug delivery vehicles. Applications 
of dendrimers typically involve the delivery of 
pharmaceutical drugs through the BBB to treat 
neurological disorders such as Alzheimer’s 
disease, stroke, and multiple sclerosis [68,69]. 
Manipulations can be made during the 
preparation of dendrimers in order to increase its 
functionality and specificity, and to make it more 
efficient in targeting the desired area of the brain. 
The drug can be either encapsulated in the 
dendrimers or attached to the periphery by 
covalent or ionic interactions [69,70]. There exist 
many types of dendrimers used in biomedical 
research, such as the poly-(propylene-imine) 
(PPI), polyether-copolyester (PEPE) and PEG 
dendrimers [65,67]. However, the most widely 
studied are the poly-(amidoamine) (PAMAM) 
dendrimers [71]. Studies have shown that 
PAMAM dendrimers can diffuse in the central 
nervous system and penetrate living neurons 
[71,72]. Moreover, in-vitro studies demonstrated 
that this drug delivery system presents little 
cytotoxicity in brain capillary endothelial cells, 
and can be effectively used to deliver anticancer 
drugs to the brain [73,74]. Taken all together, 
dendrimers are an excellent choice of a delivery 
system because of their potential to deliver 
therapeutic drugs to the brain, and because they 
have shown great promise in the treatment of 
neurological diseases 
 
4.4 Microcapsules and Polymeric Nano-
particles 
 
Microencapsulation is a technique during which a 
coating surrounds droplets of a solution in order 
to generate spherical microcapsules, using 
different types of proteins and polymers. It is 
widely accepted that microencapsulation is a 
promising tool in biomedical research that 
enables the delivery of pharmaceutical drugs to 
targeted areas of the body [75,76]. The coating 
of the microcapsules is generally made of 
sodium alginate, and it’s used to protect the 
entrapped material from the external 
environment [75]. Studies have shown that by 
using microcapsules of very small size (100-200 
microm), scientists could bypass the BBB and 
deliver therapeutic agents to specific areas of the 
brain [77]. They demonstrated that small 
microcapsules loaded with a recombinant gene 
product display high stability and mechanical 
strength, and were very efficient in treating 
neurological deficits in rodents [77]. 
 
Another carrier of choice for drug delivery across 
the BBB is the polymeric nanoparticle [78,79]. 
Nanoparticles are solid colloidal particles of very 
small size (1-1000nm) that have been frequently 
used as a drug delivery platform because of their 
high loading capacity, bioavailability, high 
stability, and targeted delivery [80]. They can be 
made of natural or synthetic polymers that 
constitute a thin envelope surrounding the 
entrapped material [81,82]. Moreover, the 
surface of the nanoparticle can be coated with 
molecules that help increase its half-life. 
Examples include PEG-coated nanoparticles, 
which exhibits enhanced stability and better 
accumulation into the brain [78]. The 
nanoparticle can also be coated with small 
ligands, such as antibodies, proteins and 
peptides, in order to target specific sites within 
the brain or even specific organelles within the 
cell [83,84]. A recent study using nanoparticles 
conjugated with a trans-activating transcriptor 
peptide has shown that coated nanoparticles 
were able to cross the BBB more efficiently and 
accumulate in neuronal cells in much higher 
proportions [85]. In summary, nanoparticles can 
be coated to move freely across the BBB, and 
their ability to enhance drug delivery and 
therapeutic efficacy make them an ideal choice 




Because of the enormous challenge faced by 
pharmaceutical companies and academics to 
develop therapies that could effectively treat 
brain diseases, a lot of attention is given on the 
understanding of the physiology and transport 











emerges as one of the most important tool in 
biotechnology due to its ability to enable drug 
targeting and delivery to specific areas of the 
brain [50]. In this review, we examined the 
functions and physiological aspects of the BBB 
as well as the role of its physical barriers, such 
as the tight and adherens junctions, in creating 
an impermeable boundary between the brain and 
the bloodstream. We also looked at the different 
transport mechanisms that could be used to 
penetrate the BBB. While this barrier restricts 
access to most foreign molecules such as drugs, 
it facilitates the penetration of nutrients essential 
for normal metabolism to reach brain tissues 
[71]. The main goal of this review was to study 
the feasibility of a new nanotechnology-based 
strategy to cross the BBB and deliver therapeutic 
agents to the brain. All of the studies presented 
in this review have illustrated the benefits of 
using nanocarriers for drug delivery, which 
include micelles, liposomes, dendrimers, 
microcapsules and polymeric nanoparticles. 
These delivery systems show superior stability, 
high biocompatibility, and enhanced drug 
distribution and release across the BBB. 
However, our knowledge of the neurobiological 
processes that regulate the function of the BBB 
is still very limited, and more work needs to be 
done to fully understand its implication in 
neurological disorders such as brain tumor and 
inflammation. Moreover, future research needs to 
focus on investigating the safety and clinical 
efficiency of using nanotechnology in humans for 
drug delivery across the BBB as a long-term 
therapy for patients with severe neurological 
disorders. 
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